Rocket Pharmaceuticals To Acquire Renovacor, Extending Leadership In Aav-Based Cardiac Gene Therapy
Acquiring Company
Rocket Pharmaceuticals
Acquired Company
Renovacor, Inc.
New YorkGreenwhichBiotechnologyHealth CareGeneticsTherapeuticsBiotechnologyHealth CareGeneticsTherapeuticsDescription
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage, clinical biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders with high unmet need, and Renovacor, Inc. (NYSE: RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases, today announced a definitive agreement under which Rocket will acquire Renovacor in an all-stock transaction for an implied value of approximately $2.60 per share, based on the volume weighted average trading price of Rocket shares of $15.51 for the 30 trading days through and including Monday, September 19, 2022. The boards of directors of both companies have unanimously approved the transaction, which is currently expected to close by the first quarter of 2023.
Other recent acquisitions in Genetics and Therapeutics
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Solid Biosciences Announces Acquisition Of Aavantibio And Concurrent $75 Million Private Placement, $75M (September 30, 2022)
- Bristol Myers Squibb And Turning Point Therapeutics Announce Expiration Of Hsr Act Waiting Period And Clearance From Federal Cartel Office Of Germany Related To Pending Acquisition Of Turning Point Therapeutics (August 16, 2022)
- Atossa Therapeutics, Inc. To Acquire Stake In Privately Held Dynamic Cell Therapies As Part Of Overall Car-T Strategy (November 1, 2022)
- Lilly To Acquire Akouos To Discover And Develop Treatments For Hearing Loss (October 18, 2022)
- Pfizer Completes Acquisition Of Global Blood Therapeutics (October 5, 2022)
- Pfizer Completes Acquisition Of Biohaven Pharmaceuticals (October 3, 2022)
Who to call at Rocket Pharmaceuticals, and when
When Rocket Pharmaceuticals changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Rocket Pharmaceuticals raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Rocket Pharmaceuticals, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Rocket Pharmaceuticals. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Rocket Pharmaceuticals makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Renovacor, Inc.?
Renovacor, Inc. was acquired by Rocket Pharmaceuticals, based in New York. The deal was reported on September 20, 2022. Rocket Pharma (NASDAQ: RCKT) is a fully-integrated, clinical-stage company seeking gene therapy cures. Rocket Pharmaceuticals is publicly traded (RCKT) and operates in Biotechnology.
When did Rocket Pharmaceuticals acquire Renovacor, Inc.?
Rocket Pharmaceuticals's acquisition of Renovacor, Inc. was reported on September 20, 2022. Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage, clinical biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders with high unmet need, and Renovacor, Inc. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Renovacor, Inc. do?
Renovacor is a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases. It is privately held, operating in Biotechnology, and is based in Greenwhich.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.